Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of cisplatin + docetaxel vs oxaliplatin + docetaxel in advanced NSCLC
2008-002197-35Phase 2Completed
- Sponsor
- Krankenhaus Nordwest
- Start
- Jun 2008
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in non-small cell lung cancer (NSCLC) comparing cisplatin + docetaxel with oxaliplatin + docetaxel (2 arms). Primary endpoints: Objective response rate and Safety and tolerability. Started Jun 2008; status: completed.
02
Drugs
docetaxelcisplatinoxaliplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2008-002197-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002197-35.